Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Receives Nasdaq Delisting Notice; Plans to Appeal

NEW YORK (GenomeWeb News) – Exact Sciences has received notice from the Nasdaq Stock Market indicating that its stock is subject to delisting because it has not regained compliance with exchange’s requirement of a minimum $50 million market capitalization.
Exact said today that it received the letter from the Nasdaq’s Listing Qualifications Staff on Aug. 12.
In July, Nasdaq warned Exact that it was in danger of non-compliance with the market cap listing requirement. The company had until Aug. 11 to regain compliance by maintaining a minimum $50 million market value for at least 10 consecutive business days.
Exact’s market capitalization is currently $25 million.
In its Aug. 12 letter, Nasdaq said that Exact’s shares would be suspended at the opening of business on Aug. 21 unless the company requests a hearing before a Nasdaq Listing Qualifications Panel.
Exact said that it plans to request a hearing before the panel, “which will postpone any delisting action until the panel renders a decision subsequent to the hearing.”

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.